Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on October 15, 2015, covering events occurring on October 9, 2015, and October 12, 2015. The Company is a Delaware corporation focused on developing and commercializing pharmaceutical products, specifically highlighting its product Oxtellar XR®.
Key Financial Metrics
This filing is a current report regarding specific corporate events and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
- Change in Certifying Accountant: The Company dismissed Ernst & Young LLP as its independent registered public accounting firm effective October 12, 2015. The dismissal followed a competitive process and was approved by the Audit Committee and Board of Directors. There were no disagreements with Ernst & Young LLP regarding accounting principles, practices, or audit scope during the two fiscal years ended December 31, 2014, and the subsequent interim period.
- Engagement of New Accountant: The Company selected KPMG LLP as its new independent registered public accounting firm effective October 12, 2015. No consultations occurred with KPMG regarding accounting principles or reportable events prior to engagement.
- Legal Proceedings: On October 9, 2015, the U.S. District Court for the District of New Jersey denied a motion for summary judgment filed by Actavis Inc. and related entities regarding patent infringement claims against Oxtellar XR®. The Court ordered the consolidation of related civil actions.
Guidance, Outlook, and Risks
Management Commentary and Outlook: Management stated that the Company is prepared to continue vigorously litigating the patent cases against Actavis to enforce its intellectual property rights for Oxtellar XR®. A trial for the consolidated actions is anticipated to commence on November 18, 2015.
Risks and Contingencies: The primary risk highlighted is the ongoing patent litigation concerning U.S. Patent Nos. 7,722,898, 7,910,131, and 8,617,600. The denial of the defendant's motion for summary judgment indicates the case will proceed to trial, presenting a contingency regarding the protection of the Company's key product.
Investor Verification Checklist
- Verify the transition timeline and scope of work between Ernst & Young LLP and KPMG LLP for the fiscal year ending December 31, 2015.
- Monitor the status of the patent infringement trial scheduled to commence on November 18, 2015, involving Oxtellar XR® and Actavis.
- Review the letter from Ernst & Young LLP (Exhibit 16.1) to confirm no undisclosed disagreements or reportable events.
- Assess the potential financial impact of the litigation outcome on the Company's future revenue streams from Oxtellar XR®.